δ-aminolevulinic acid cytotoxic effects on human hepatocarcinoma cell lines

BMC Cancer

Volumn 2, Issue , 2002, Pages

  De Siervi, Adriana ^a   Vazquez, Elba S ^a   Rezaval, Carolina ^a   Rossetti, María V ^a   del Batlle, Alcira M ^a  

^a UNIVERSIDAD DE BUENOS AIRES   (Argentina)

Author keywords

[No Author keywords available]

Indexed keywords

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; AMINOLEVULINIC ACID; CYCLIN DEPENDENT KINASE 2; CYCLIN DEPENDENT KINASE 4; DNA FRAGMENT; GLUCOSE; HEMIN; MESSENGER RNA; PROTEIN P53; DNA; TETRAZOLIUM; THIAZOLE DERIVATIVE; THIAZOLYL BLUE;

APOPTOSIS; ARTICLE; CELL ASSAY; CELL STRAIN HEPG2; CELL SURVIVAL; CONCENTRATION RESPONSE; CONTROLLED STUDY; DNA DETERMINATION; DRUG CYTOTOXICITY; DRUG EXPOSURE; DRUG MECHANISM; DRUG SENSITIVITY; HUMAN; HUMAN CELL; LIVER CELL CARCINOMA; PROTEIN EXPRESSION; TUMOR CELL LINE; BIOSYNTHESIS; CELL CULTURE; CELL CYCLE; DOSE RESPONSE; DRUG EFFECT; LIVER TUMOR; METABOLISM;

AMINOLEVULINIC ACID; CARCINOMA, HEPATOCELLULAR; CELL CYCLE; DNA FRAGMENTATION; DNA, NEOPLASM; DOSE-RESPONSE RELATIONSHIP, DRUG; GLUCOSE; HEMIN; HUMANS; LIVER NEOPLASMS; TETRAZOLIUM SALTS; THIAZOLES; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEIN P53;

EID: 3042604456     PISSN: 14712407     EISSN: None     Source Type: Journal    
DOI: 10.1186/1471-2407-2-6     Document Type: Article

References (27)

1. Wetterberg LA: Neuropsychiatric and genetical investigation of Acute Intermittent Porphyria. Stockholm University Books, Stockholm. Sweden, 1967
2. Batlle C AM del, Riley PA: Abnormality of heme synthesis as the initial lesion in carcinogenesis. Cancer J 1991, 4:326-330
3. De Siervi A, Rossetti MV, Parera VE, Mendez M, Varela LS, Batlle C AM del: Acute intermittent porphyria: Biochemical and clinical analysis in the Argentinean population. Clinica Chimica Acta 1999, 288:63-71
4. Stein JA, Tschudy DP: Acute intermittent porphyria: a clinical and biochemichal study in 46 patients. Medicine 1970, 49:1-16
5. Bonkowsky HL, Tschudy DP, Collins A, Doherty J, Bossenmaier I, Cardinal R, Watson CJ: Repression of the overproduction of porphyrin precursors in acute intermittent porphyria by intravenous infusion of hematin. Proc Natl Acad Sci, 1971, 68:2725-2729
6. Wider de Xifra EA, Batlle C AM del, Stella AM, Malamud S: Acute intermittent porphyria. Another approach to the therapy Int J Biochem 1980, 12:812-822
7. Lithner F, Wetterberg L: Hepatocellular carcinoma in patients with acute intermittent porphyria. Acta Med. Scand. 1984, 215:271-274
8. Hardell L, Bengtsson NO, Jonsson U, Eriksson S, Larsson LG: Aetiological aspects on primary liver cancer with special regarding alcohol, organic solvents and acute intermittent porphyria. An epidemiological investigation. Br J Cancer 1984, 50:389-397
9. Kauppinen R, Mustajoky P: Acute hepatic porphyria and hepatocellular carcinoma. Br J Cancer 1988, 57:117-120
10. Onuki J, Medeiros MHG, Bechara EJH, Di Mascio P: 5 aminolevulinic acid induces single-strand breaks in plasmid pBR322 DNA in the presence of Fe2+ ions. Biochim. Biophys. Acta 1994, 1056:57-63
11. Aden DP, Fogel A, Plotkin S, Damjanov I, Knowles BB: Controlled synthesis of HBs Ag in a differentiated human liver carcinoma-derived cell line. Nature 1979, 282:615-616
12. Knowles BB, Howen CC, Aden DP: Human hepatocellular carcinoma cell lines secrete the major plasma proteins and hepatitis B surface antigen. Science (Washington DC) 1980, 209:497-499
13. Darlington GJ, Kelly JH, Buffone GJ: Growth and hepatospecific gene expression of human hepatoma cells: A defined medium. In Vitro Cell Dev 1987, 23:348-354
14. Bressac B, Galvin KM, Liang TJ, Isselbacher KJ, Wands JR, Ozturk M: Abnormal structure and expression of p53 gene in human hepatocellular carcinoma Proc Natl Acad Sci USA 1990, 87:1973-1977
15. Wilson JK, Sargent JM, Elgie AW, Hill JG, Taylor CG: A feasibility study of the MTT assay for chemosensitivity testing in ovarian malignancy. Br J 1990, 62:189-194
16. Chomczynski P, Sacchi N: Single-step method of RNA isolation by acid guanidinium thiocyanate-PhOH-chloroform extraction. Annal Biochem 1987, 162:156-159
17. Douki T, Oniki J, Medeiros MH, Bechara EJ, Cadet J, Di Mascio P: DNA alkylation by 4,5-dioxovaleric acid, the final oxidation product of 5-aminolevulinic acid. Chem Res Toxicol 1998, 11:150-157
18. Batlle A: Porphyrins, porphyrias, cancer and photodynamic therapy-a model for carcinogenesis. Photochem Photobiol B: Biol 1993, 20:5-22
19. Helson S, Braverman S, Mangiardi J: 5-Aminolevulinic Acid effects on neuronal and glial tumor cell lines. Neurochem Res 1993, 18:1255-1258
20. Washbrook R, Fukuda H, Batlle A, Rilry P: Stimulation of tetrapyrrole synthesis in mammalian epithelial cells in culture by exposure to aminolevulinic acid. Br J 1997, 75:381-387
21. Wagener F, Feldman E, de Wite T, Abraham N: Heme induce the expression of adhesion molecules ICAM-1, VCAM-1 and E selectin in vascular endothelial cells. Soc Exp Biol Med 1997, 216:456-463
22. Nath K: Heme oxygenase-1: a redoubtable response that limits reperfusion injury in the transplanted adipose liver. J Clin Invest 1999, 104:1485-1486
23. Russel V, Lamm M, Taljard J: Effects of δ-aminolevulinic acid, porphobilinogen and structurally related aminoacids on 2-deoxyglucose uptake in cultured neurons. Neurochem Res 1982, 7:
24. Raff MC, Barres BA, Burne JF, Coles HS, Ishizaki Y, Jacobso M: Programmed cell death and the control of cell survival. Philos Trans R Soc Lond B Biol Sci 1994, 345:265-271
25. Lowe SW, Bodis S, McClatchey A, Remington L, Ruley HE, Fisher DE, Housman DE, Jacks T: p53 status and the efficacy of cancer therapy in vivo. Science 1994, 266:807-809
26. Meijer L: Chemical inhibitors of cycline-dependent kinases. Trends Cell 1996, 6:393-396
27. Garrett M, Fattaey A: CDK inhibition and cancer therapy. Curr Opin Genet Develop 1999, 9:104-111